| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2015: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
|
|---|
| Outline of Final Research Achievements |
We developed for the first time a lozenge preparation containing polaprezinc (PZ), a zinc-L-carnosine. This preparation was stable and uniform after storage for up to 24 weeks, and applied to 16 patients receiving cancer chemotherapy before hematopoietic stem cell transplantation. The primary endpoint was the incidence of moderate to severe oral mucositis, while secondary endpoints were oral pain, xerostomia and taste disturbance. Oral mucositis occurred in 73% of patients without PZ treatment but in 13% of those who received PZ lozenge. PZ lozenge also reduced the incidence of oral pain, xerostomia and taste disturbance. Therefore, the present PZ lozenge was found to be highly effective for prevention of chemotherapy-induced oral mucositis.
|
